Literature DB >> 33768073

Crohn's Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab.

Aasem Abu Shtaya1,2, Shai Cohen1,2, Yana Kogan2,3, Michal Shteinberg2,3, Ori Sagool2,4.   

Abstract

Crohn's disease is a chronic inflammatory bowel disease that can affect any part of the GI tract, which is frequently associated with extra-intestinal manifestations. Pulmonary parenchymal disease is very uncommon and usually considered to be debilitating and harder to diagnose. Pulmonary granulomas are rarely described in the literature as a complication of Crohn's disease. Here, we present a patient with Crohn's disease exacerbation who developed granulomatous lung disease under treatment with vedolizumab. Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease. LEARNING POINTS: Pulmonary parenchymal diseases are rare in Crohn's disease but they can be debilitating and life-threatening as they are usually tardily diagnosed; awareness of this association is of high value and could potentially shorten the time to a definite diagnosis.Pulmonary manifestations of Crohn's disease could be subclinical without any respiratory complaints and not diagnosed with conventional imaging modalities such as chest x-ray.Gut-selective biologic agents could lead to the emergence of extra-intestinal manifestations due to upregulation of multiple pro-inflammatory cytokines. © EFIM 2021.

Entities:  

Keywords:  Crohn’s disease; granuloma; infliximab; vedolizumab

Year:  2021        PMID: 33768073      PMCID: PMC7977061          DOI: 10.12890/2021_002265

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  5 in total

1.  Antibody secretion by human intestinal mononuclear cells from normal controls and inflammatory bowel disease patients.

Authors:  R P MacDermott; G S Nash; M H Nahm
Journal:  Immunol Invest       Date:  1989 Jan-May       Impact factor: 3.657

Review 2.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.

Authors:  Donata Lissner; Rainer Glauben; Kristina Allers; Elena Sonnenberg; Christoph Loddenkemper; Thomas Schneider; Britta Siegmund
Journal:  Am J Gastroenterol       Date:  2018-01       Impact factor: 10.864

4.  A common mucosal immunologic system involving the bronchus, breast and bowel.

Authors:  J Bienenstock; M McDermott; D Befus; M O'Neill
Journal:  Adv Exp Med Biol       Date:  1978       Impact factor: 2.622

5.  A Rare Cause of Pulmonary Nodules.

Authors:  Michael Tsuyoshi Chew; Eric Chak; Karen Matsukuma
Journal:  Case Rep Gastroenterol       Date:  2016-10-28
  5 in total
  2 in total

1.  Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report.

Authors:  Jie Zhang; Mei-Hong Liu; Xue Gao; Chang Dong; Yan-Xia Li
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

2.  Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis.

Authors:  Wanwan Zhu; Tianhao Zhao; Jun Wei; Damin Chai; Cancan Zhao; Yu Zhu; Min Deng
Journal:  Front Med (Lausanne)       Date:  2022-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.